Wed.Jul 17, 2024

article thumbnail

Vaccination slashes risk of long Covid, says large study tracing cases through Delta and Omicron variants

STAT

Vaccination lowers the chance of developing long Covid, according to a large new study that also found that the risk of serious complications has diminished but not disappeared as new coronavirus variants emerged. The study, published Wednesday in the New England Journal of Medicine , compared the health records of more than 440,000 Veterans Affairs patients who were infected with Covid-19 with records of more than 4 million uninfected people.

Vaccines 364
article thumbnail

Amylyx’s CEOs on their ALS setback and quest to revamp the pipeline

PharmaVoice

Co-CEOs Josh Cohen and Justin Klee reflect on what they learned from Relyvrio’s failure and how they’re carrying those lessons forward with other drugs.

130
130
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

As GLP-1 sales surge, insulin users fear Novo Nordisk and Eli Lilly will move on without them

STAT

Around the world, patients suddenly can’t find enough of the insulins made by companies they have long relied on to do so. In the U.S., Novo Nordisk’s recent decision to discontinue a product has left patients with fewer options. At the same time, patients are encountering shortages of other products from Novo and Eli Lilly. For months, pharmacies have been running out of vials of certain insulins that patients use to fill the pumps they wear on their body.

Diabetes 363
article thumbnail

A new biotech tackling IBD joins a race against Lilly and Gilead for a promising pill

PharmaVoice

Ensho Therapeutics just launched but is already generating buzz with its phase 2-ready clinical program for inflammatory bowel disease.

130
130
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Bone marrow donors needn’t be perfect match, study says, paving way for more equitable access

STAT

As a hematologist-oncologist in Miami, Mikkael Sekeres always hopes his patients will find a perfect match for the bone marrow transplant they need to save their lives — but he doesn’t expect it. Most of his patients are Latino or African American, and rates of perfect matches are much lower for racial or ethnic minorities. That gloomy picture could soon change.

349
349
article thumbnail

Endo Recalls Clonazepam Because of Mislabeling

PharmaTech

The company has issued a voluntary recall of one lot of Clonazepam Orally Disintegrating Tablets, USP (C-IV), because of incorrect strength published on product carton.

118
118

More Trending

article thumbnail

Obesity pill from Roche shows promising weight loss in small study

BioPharma Dive

Treatment led to "clinically meaningful" weight loss over four weeks, but longer studies will be needed to compare it to Wegovy and Zepbound.

120
120
article thumbnail

STAT+: Gilead’s chief medical officer to leave as R&D efforts stall

STAT

Gilead Sciences’ chief medical officer will leave the company early next year as the drugmaker struggles to find new areas of growth beyond its core portfolio of HIV medicines. Merdad Parsey, who joined Gilead in 2019, will stay in his post until the first quarter of next year as the company looks for a successor, Gilead said in a press release Wednesday.

333
333
article thumbnail

Merck launches GMP-compliant cell culture media line in China

Pharmaceutical Business Review

The new line, representing an investment of nearly €6.6m ($7.1m), is located at the Life Science Center in Nantong. This development is aimed at meeting the increasing local demand for high-quality custom CCM, critical in the production of biopharmaceuticals, vaccines, and new therapeutics. The commercialisation of the Nantong facility’s production line will allow Chinese customers to access established range of custom CCM products and services of Merck.

Vaccines 107
article thumbnail

STAT+: A second Roche obesity drug shows promise in early studies

STAT

LONDON — Roche on Wednesday reported positive early data from another of the obesity drug candidates that it picked up through an acquisition late last year, bolstering the case it could become a player in the competitive weight-loss medicine field.   The company said its once-daily pill, called CT-996, led to a placebo-adjusted average weight loss of 6.1% after four weeks in patients with obesity who did not have diabetes.

Diabetes 334
article thumbnail

Why Every Small Business Needs an HCM Solution: A Comprehensive Guide

Managing HR tasks like payroll, compliance, and employee data can overwhelm small businesses. That’s where a Human Capital Management (HCM) solution comes in. Our eBook, Why Every Small Business Needs an HCM Solution: A Comprehensive Guide , shows how an HCM system automates tedious processes, ensuring your business stays compliant and efficient. You’ll learn how to simplify payroll, eliminate costly errors, and empower your employees with self-service tools.

article thumbnail

Advances in neurological research highlight breakthrough therapies

Express Pharma

Q. How will advanced methodologies like screening and sophisticated models benefit patients in India and around the world who suffer from neurological disorders? Response: Advanced methodologies like high-throughput screening and sophisticated models, such as human iPSC-derived organoids, fast-track the process of identification and validation of potential therapeutic compounds which is otherwise is slow and cumbersome.

article thumbnail

Opinion: Listen: Empathy should be the first response to people with vaccine injury, fears

STAT

For scientists and medical professionals well versed in the safety and effectiveness of vaccines, it is often too easy to write off the concerns of people who fear them, or feel they have been injured by them. But vaccine expert Kizzmekia S. Corbett-Helaire argues that professionals should be more empathetic when it comes to listening to these concerns, and that understanding them may help developers make better vaccines.

Vaccines 307
article thumbnail

In strengthening Spravato sales, a positive sign for psychedelic drugs

BioPharma Dive

Jefferies analyst Andrew Tsai views growing sales for J&J’s depression treatment as evidence that psychedelics like it can be commercially viable.

113
113
article thumbnail

STAT+: With resignations of top leaders, Cassava Sciences exposes a dark, ugly corner of the Alzheimer’s disease world

STAT

Cassava Sciences is imploding — and as it crumbles, a dark, ugly corner of the Alzheimer’s disease world is being exposed and will hopefully get cleaned up. Remi Barbier, Cassava’s longtime CEO, has resigned and is also leaving the board, the company announced Wednesday. Lindsay Burns, Cassava’s senior vice president of neuroscience, is gone, too.

326
326
article thumbnail

Best Practices to Streamline Compensation Management: A Foundation for Growth

Speaker: Joe Sharpe and James Carlson

Payroll optimization can be one of the most time-consuming and complex factors of small business management. Yet, organizations that crack the code on streamlining employee compensation often discover innovative avenues for growth. With the right strategies in place, outsourcing and streamlining payroll processes can result in substantial time and resource savings.

article thumbnail

Allergy Medications As Deprescribing Targets

Med Ed 101

Allergic rhinitis is a very common condition. I’ve encountered numerous patients throughout my career who take more than one medication to help keep their symptoms at bay. When reviewing polypharmacy cases, I do consider allergy medications as deprescribing targets because oftentimes allergy medications are added and the original success of the first agent is not […] The post Allergy Medications As Deprescribing Targets appeared first on Med Ed 101.

105
105
article thumbnail

STAT+: Why clinical trials for digital therapeutics are getting more rigorous

STAT

Faced with widespread skepticism about the value of digital therapies, Swing Therapeutics in early 2022 set out to make the strongest case possible for its app-based treatment for fibromyalgia. In a year-long pivotal trial for Swing’s treatment, called Stanza, participants were told they were receiving one of two potentially effective treatments for fibromyalgia.

305
305
article thumbnail

At Long Last, FDA Unveils Plan for Rare Disease Innovation Hub

FDA Law Blog: Biosimilars

By Sarah Wicks & James E. Valentine & Frank J. Sasinowski — On July 17, 2024, FDA announced the establishment of a Rare Disease Innovation Hub (the “Hub”) to enhance and improve outcomes for patients with rare diseases and conditions by focusing on rare disease drug and biological product development across the Agency’s Center for Drug Evaluation and Research (“CDER”) and Center for Biologics Evaluation and Research (“CBER”).

article thumbnail

STAT+: Data privacy startup raises $30 million, to ease health care providers’ regulatory burden

STAT

Federal guidance restricting hospital websites’ use of third-party trackers along with the proliferation of direct-to-consumer health services is spawning a new crop of health tech startups promising to help beleaguered providers stay on the right side of the law. Among them is San Francisco startup Freshpaint, which on Wednesday announced a $30 million Series B round to sell its privacy platform to providers, pharmacies, insurers.

Hospitals 318
article thumbnail

Enhance Healthcare Efficiency With Top Payroll & HCM Services

Running a healthcare facility requires precision and care, not just for patients but also for your staff. Our guide, "A Buyer’s Guide to Payroll & HCM Services," helps healthcare providers choose the best provider. Efficient payroll management ensures timely, accurate payments, critical for maintaining staff morale and trust. Compliance support helps navigate complex healthcare regulations and avoid costly fines.

article thumbnail

ARRS pharmacists dissatisfied with pay and progression

The Pharmacist

EXCLUSIVE Pharmacists working in Additional Roles Reimbursement Scheme (ARRS) jobs have raised concerns about salary and career progression in our recent snapshot survey. However, respondents reported positive experiences of inductions, training and support. The survey, run in conjunction with our sister titles Healthcare Leader and Pulse PCN, had 44 ARRS pharmacist respondents.

104
104
article thumbnail

STAT+: A Senate bill was touted as a cure for ‘patent thickets.’ Some say the drug industry watered it down

STAT

A clutch of headlines last week suggested the U.S. Senate had achieved a breakthrough in the battle to prevent pharmaceutical companies from abusing the patent system, an issue that has been blamed for boosting prescription drug costs for Americans. But while the Senate bill  clearly represents a step forward, the impact will not be nearly as great as originally intended by lawmakers due to industry lobbying.

article thumbnail

European Pharmacopoeia makes milestone pyrogen testing commitment

European Pharmaceutical Review

European Pharmacopoeia has confirmed it will remove the rabbit pyrogen test (RPT) from its monographs. This milestone decision was made during the Ph. Eur.’s 179th session in June 2024. The RPT has been the traditional detection method for pyrogens, the European Directorate for the Quality Of Medicines (EDQM) explained. In June 2021, the European Pharmacopoeia Commission (EPC) committed to completely replace the RPT in the 59 Ph.

98
article thumbnail

STAT+: Pharmalittle: We’re reading about Roche obesity drug data, fallout from the Menendez verdict, and more

STAT

Hello, everyone, and how are you today? We are doing just fine, thank you, especially since the middle of the week is upon us. After all, we have made it this far, so we are determined to hang on for another couple of days. And why not? The alternatives — at least those we can identify — are not so appetizing. And what better way to make the time fly than to keep busy.

Diabetes 249
article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

12 Questions with Dr James Burt

pharmaphorum

Get insights into Dr James Burt's leadership as CEO of Pharmanovia through a 12-question interview that covers his background, achievements, and vision for the company.

110
110
article thumbnail

It’s happy hour (for now) for Alnylam

STAT

Good morning and happy Wednesday. Today we’re talking about insulin, pharma’s ties with politicians, and some nice champagne. The need-to-know this morning Roche shares traded higher on positive weight-loss results from an early study of an oral GLP-1 drug candidate that the Swiss pharma giant picked up in an acquisition last year. Johnson & Johnson reported second-quarter earnings that topped Street consensus, but its profit outlook for the remainder of the year was trimmed sl

Diabetes 187
article thumbnail

King’s Speech confirms tobacco and vapes bill

The Pharmacist

The new Labour government will introduce a bill to progressively increase the age at which people can buy cigarettes and impose limits on the sales and marketing of vapes, His Majesty the King has confirmed in a speech today. Under the proposed Tobacco and Vapes bill, children born on or after 1 January 2009 will […] The post King’s Speech confirms tobacco and vapes bill appeared first on The Pharmacist.

101
101
article thumbnail

Fischer Medical Ventures secures marketing rights for Nanyang Biologics’ nutraceuticals in India, Middle East, & ASEAN

Express Pharma

Fischer Medical Ventures (Fischer MV), has confirmed its collaboration with Singapore company, Nanyang Biologics (NYB), a drug discovery company dedicated to create transformative nutraceuticals derived from natural plants and herbs. This strategic partnership aims to revolutionise healthcare industry by delivering innovative, evidence-based products that enhance overall health and well-being, guided by scientific research and data-driven methodologies.

article thumbnail

5 Reasons to Upgrade Your Pharmacy Management Software

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

article thumbnail

Darolutamide meets primary endpoint in Phase III ARANOTE trial

World Pharma News

The Phase III ARANOTE trial, investigating darolutamide plus ADT in patients with metastatic hormone-sensitive prostate cancer (mHSPC), has met its primary endpoint of rPFS. Darolutamide plus ADT significantly increased rPFS compared to placebo plus ADT. The safety data were comparable between both treatment arms and reconfirm the established tolerability profile of darolutamide in advanced prostate cancer.

100
100
article thumbnail

Zydus announces non-exclusive patent licensing agreement with Takeda for ‘Vault’ (Vonoprazan) in India

Express Pharma

Zydus Lifesciences (including its subsidiaries/affiliates hereafter referred to as “Zydus”) has entered into a non-exclusive patent licensing agreement with Takeda Pharmaceutical Company to market the novel Potassium Competitive Acid Blocker (P-CAB) Vonoprazan in India. The drug will be marketed under the brand name of Vault in India. Under the terms of this agreement, Zydus will be marketing the drug in India.

article thumbnail

Vertex, Orum partner on safer pre-treatment for gene meds

pharmaphorum

Vertex Pharma has teamed up with Orum Therapeutics to develop a conditioning regimen, used to prepare patients to receive gene-editing medicines, that it hopes will offer a more tolerable alternative to current chemotherapy options.Vertex is paying $15 million upfront to get the ball rolling on the collaboration, which could be worth up to $945 million if it exercises options to use the technology for three developmental programmes and all of them hit various milestones.

article thumbnail

AGC Pharma Chemicals partners with AbilityPharma on pancreatic cancer treatment

Express Pharma

AGC Pharma Chemicals, an international Contract Development and Manufacturing Organisation (CDMO) company based in Spain and Japan that develops and manufactures active pharmaceutical ingredients (APIs) and intermediates, and AbilityPharma, a biotech company based in Catalonia, have announced a strategic collaboration for the development of an API for the treatment of pancreatic cancer, ABTL0812, currently in clinical trials.

article thumbnail

The US Biosecure Act threatens to destabilise the pharmaceutical industry 

Pharmaceutical Technology

In January, the US House Select Committee on the Strategic Competition between the US and the Chinese Communist Party introduced the Biosecure Act.

98